Commerce’s Sept. 23 guidance in the Federal Register drew the clearest line yet through the government’s pharmaceutical tariff program: generic drugs, for now, stay outside it, while patented imports already face a 100% tariff that took effect July 31 for the first group of drugmakers and September 29 for the rest. The split decides which prescriptions carry a new import cost and which do not, based on how a drug was approved rather than its price or its place in a household’s medicine cabinet. Commerce also built a one-year review into the generic exemption, so the line the guidance draws today is not necessarily where it will sit next year.
What counts as a generic pharmaceutical article
The notice states that Section 232 pharmaceutical tariffs do not currently apply to generic pharmaceutical products and associated ingredients, and it defines a generic pharmaceutical article broadly: an active ingredient or any component of a finished-dose product used in a drug or biosimilar biological product approved through a generic or biosimilar pathway.
That definition folds biosimilars into the same exemption as ordinary generic tablets. A biosimilar version of an injectable arthritis or diabetes drug, cleared through the FDA’s biosimilar pathway rather than as a new brand-name product, is treated the same as a small-molecule generic for tariff purposes. The distinction that matters is regulatory, not clinical: two drugs that treat the same condition can land on opposite sides of the tariff line depending on how each one was approved, not on how common or effective it is.
Which side of that line a specific prescription falls on turns on the drug’s FDA approval pathway, not its brand recognition. A medicine listed in the FDA’s Orange Book as an approved generic, or in the Purple Book as a licensed biosimilar, qualifies for the exemption; the same chemical entity sold only under its original brand name, before any generic or biosimilar competitor reaches the market, does not. That approval-pathway test is the same one the FDA already uses for other purposes, so the tariff exemption did not require Commerce to build a new sorting system from nothing.
The protection is also explicitly temporary. Commerce must review within one year of the tariffs’ effective date whether to extend duties to generic drugs and their ingredients, according to a client alert from trade attorneys at Crowell & Moring, which means the September 2026 exemption describes where the policy stands today, not a permanent carve-out a household can assume will still hold next year.
The exemption is federal; the filing is local: The generic-drug exemption and the 100% patented-drug tariff both turn on Washington’s own classification, not on anything a household requests. Compare the circuit-breaker credit that includes renters in The Senior Property Tax & Home-Cost Relief Kit.
The 100% rate, and the narrower paths around it
Patented pharmaceutical imports covered by Proclamation 11020 face a 100% ad valorem duty rate, Customs and Border Protection’s implementing guidance says, combining the standard column-one duty with the new Section 232 rate. That rate took effect July 31, 2026 for pharmaceutical companies listed in the proclamation’s Annex III and September 29, 2026 for every other company whose patented products are covered.
Two paths reduce that rate without eliminating it. A company with a Commerce-approved plan to move manufacturing onshore pays a 20 percent rate instead of 100%, a reduction available through April 2, 2030; a company that adds a separate pricing agreement with the Department of Health and Human Services can bring that same rate to zero through January 20, 2029, in exchange for detailed onshoring commitments and semiannual progress reports.
Qualifying for either reduced rate takes more than a promise of future factories. Commerce’s onshoring procedures require a company to spell out which part of its existing patented portfolio it will move onshore, by product, volume and value, along with the share of U.S. and global sales already produced domestically, investment and production milestones running through January 2029, and audited progress reports twice a year. Preferential treatment applies only to that company’s own branded products, not to drugs it acquires afterward.
Neither path is open to a company that simply imports a patented drug without also committing to move production to the United States, so the 100% rate remains the default for patented pharmaceuticals whose manufacturers have not signed one of Commerce’s onshoring agreements.
Why the split still exposes brand-name and biologic drugs
Proclamation 11020 justifies the tariff on production-location grounds: it states that about 53 percent of patented pharmaceutical products distributed in the United States are produced abroad, and that only about 15% of patented active pharmaceutical ingredients are manufactured domestically by volume.
That imbalance is why patented drugs, not generics, carry the new duty. The category includes many newer biologic treatments for diabetes, autoimmune disease and cancer that do not yet have a generic or biosimilar substitute, and a 100% duty on the imported product is a cost that a manufacturer or importer can pass along the same way any other import cost gets built into what a drug ultimately costs.
For a Medicare beneficiary taking one of those biologics, the effect runs through the supply chain rather than through Medicare’s own price rules. Part D plans set formulary tiers and negotiate rebates on their own schedule, separate from any tariff, but a manufacturer facing a new 100% cost on units it brings into the country has an added expense to weigh before it ever reaches the price a plan negotiates against.
For a prescription that already has a generic or biosimilar version, the September guidance leaves the import math unchanged. For a brand-name drug that has none, the 100% rate applies to the imported product unless its maker holds one of the onshoring or HHS pricing agreements Commerce has approved. The same Sept. 23 notice also opens a separate, far narrower zero-tariff lane for a short list of specialty drugs from specific trading partners, a distinct carve-out from the generic-patented split described here.
Relief that isn’t automatic either
Commerce’s guidance sorts prescriptions into generic, patented and onshored categories with different tariff rates, but none of that changes what happens to a fixed household budget once other costs keep climbing. Property taxes, heating bills and home-repair costs do not arrive with an automatic discount either, and relief for them typically has to be requested rather than granted on its own.
The Senior Property Tax & Home-Cost Relief Kit lays out the 5 kinds of property-tax relief alongside an application log and renewal calendar, built for tracking what has already been filed.
See the 5 kinds of relief in The Senior Property Tax & Home-Cost Relief Kit.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
